Trial Profile
Phase I/II trial of Alpha-galactosidase (MOSS-AGAL) in patients with Fabry Disease
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 24 Sep 2016
Price :
$35
*
At a glance
- Drugs Alpha galactosidase (Primary)
- Indications Fabry's disease
- Focus Adverse reactions; Therapeutic Use
- 24 Sep 2016 New trial record
- 09 Mar 2015 According to a Greenovation Biotech media release, company is working on our regulatory package for this trial.